ArticleFrontiers in oncology2025
Testicular lymphoma of 63 patients: a Chinese retrospective, real-world study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To suggest the difference between primary and secondary testicular lymphoma, and to manifest the clinical characteristics, treatment modalities and prognostic factors of primary testicular lymphoma. Method: This study included all lymphoma patients with testicular involvement treated at our institution between October 2012 and May 2024. We retrospectively collected data on their clinical characteristics, treatment approaches, and outcomes for further analysis. Result: A total of 50 primary testicular lymphoma (PTL) patients and 13 secondary testicular lymphoma (STL) patients were enrolled, with diffuse large B-cell lymphoma (DLBCL) being the most common subtype. After a median follow-up of 36.0 months (range: 1.1-117.5), the median progression-free survival (PFS) was 105.9 months for PTL patients and 16.8 months for STL patients. The median overall survival (OS) was 106 months for PTL and 23.8 months for STL. Among the 46 primary DLBCL (PT-DLBCL) cases, half received central nervous system (CNS) prophylaxis, and 7 patients (15.2%) experienced CNS relapse. Patients who received maintenance therapy after orchiectomy and first-line treatment exhibited prolonged PFS. Radiotherapy was associated with improved PFS, while the double-expressor phenotype was linked to poorer OS. Conclusion: PTL suggested distinct histopathological features, clinical responses, and survival outcomes compared to STL. A combined treatment strategy involving orchiectomy followed by chemotherapy, consolidation therapy, and radiotherapy is recommended for PT-DLBCL. As intrathecal methotrexate did not significantly reduce CNS recurrence, alternative prophylactic strategies should be explored for high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.